全文获取类型
收费全文 | 210289篇 |
免费 | 15213篇 |
国内免费 | 749篇 |
专业分类
耳鼻咽喉 | 2284篇 |
儿科学 | 5482篇 |
妇产科学 | 4309篇 |
基础医学 | 27104篇 |
口腔科学 | 4512篇 |
临床医学 | 20004篇 |
内科学 | 44888篇 |
皮肤病学 | 2754篇 |
神经病学 | 20303篇 |
特种医学 | 6953篇 |
外国民族医学 | 13篇 |
外科学 | 32916篇 |
综合类 | 3411篇 |
现状与发展 | 2篇 |
一般理论 | 291篇 |
预防医学 | 19062篇 |
眼科学 | 4373篇 |
药学 | 14390篇 |
1篇 | |
中国医学 | 374篇 |
肿瘤学 | 12825篇 |
出版年
2023年 | 843篇 |
2022年 | 1405篇 |
2021年 | 3440篇 |
2020年 | 2105篇 |
2019年 | 3390篇 |
2018年 | 3967篇 |
2017年 | 3212篇 |
2016年 | 3410篇 |
2015年 | 4066篇 |
2014年 | 6095篇 |
2013年 | 8822篇 |
2012年 | 13125篇 |
2011年 | 14319篇 |
2010年 | 8096篇 |
2009年 | 7304篇 |
2008年 | 13588篇 |
2007年 | 14424篇 |
2006年 | 13918篇 |
2005年 | 14393篇 |
2004年 | 13806篇 |
2003年 | 12899篇 |
2002年 | 12435篇 |
2001年 | 1875篇 |
2000年 | 1459篇 |
1999年 | 2047篇 |
1998年 | 2830篇 |
1997年 | 2437篇 |
1996年 | 2206篇 |
1995年 | 1953篇 |
1994年 | 1755篇 |
1993年 | 1655篇 |
1992年 | 1210篇 |
1991年 | 1150篇 |
1990年 | 1057篇 |
1989年 | 956篇 |
1988年 | 1012篇 |
1987年 | 1018篇 |
1986年 | 1002篇 |
1985年 | 1083篇 |
1984年 | 1481篇 |
1983年 | 1463篇 |
1982年 | 1814篇 |
1981年 | 1639篇 |
1980年 | 1555篇 |
1979年 | 812篇 |
1978年 | 958篇 |
1977年 | 932篇 |
1976年 | 831篇 |
1975年 | 682篇 |
1974年 | 666篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
112.
113.
114.
115.
116.
John L Hayes 《American journal of orthodontics and dentofacial orthopedics》2005,128(5):557-8; author reply 558
117.
Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. 总被引:3,自引:0,他引:3
Amit Shah William A Swain Donna Richardson John Edwards Duncan J Stewart Catherine M Richardson Daniel E B Swinson Dipika Patel J Louise Jones Kenneth J O'Byrne 《Clinical cancer research》2005,11(8):2930-2936
Akt, a Serine/Threonine protein kinase, mediates growth factor-associated cell survival. Constitutive activation of Akt (phosphorylated Akt, P-Akt) has been observed in several human cancers, including lung cancer and may be associated with poor prognosis and chemotherapy and radiotherapy resistance. The clinical relevance of P-Akt in non-small cell lung cancer (NSCLC) is not well described. In the present study, we examined 82 surgically resected snap-frozen and paraffin-embedded stage I to IIIA NSCLC samples for P-Akt and Akt by Western blotting and for P-Akt by immunohistochemistry. P-Akt protein levels above the median, measured using reproducible semiquantitative band densitometry, correlated with a favorable outcome (P = 0.007). Multivariate analysis identified P-Akt as a significant independent favorable prognostic factor (P = 0.004). Although associated with a favorable prognosis, high P-Akt levels correlated with high tumor grade (P = 0.02). Adenocarcinomas were associated with low P-Akt levels (P = 0.039). Akt was not associated with either outcome or clinicopathologic variables.Cytoplasmic (CP-Akt) and nuclear (NP-Akt) P-Akt tumor cell staining was detected in 96% and 42% of cases, respectively. Both CP-Akt and NP-Akt correlated with well-differentiated tumors (P = 0.008 and 0.017, respectively). NP-Akt also correlated with nodal metastases (P = 0.022) and squamous histology (P = 0.037).These results suggest P-Akt expression is a favorable prognostic factor in NSCLC. Immunolocalization of P-Akt, however, may be relevant as NP-Akt was associated with nodal metastases, a known poor prognostic feature in this disease. P-Akt may be a potential novel therapeutic target for the management of NSCLC. 相似文献
118.
119.
David W. Farley DDS John D. Jones DDS Robert J. Cronin DDS MS 《Journal of prosthodontics》1998,7(2):84-90
Phonetics, esthetics, function, and comfort form the foundation of a successful dental prosthesis. A review of the mechanics of speech as well as common speech problems encountered with a removable maxillary prosthesis are presented. The use of a palatogram to aid the clinician in the assessment and resolution of speech problems associated with a maxillary denture is demonstrated. 相似文献
120.
Dmitri Artemov Zaver M. Bhujwalla Ross J. Maxwell John R. Griffiths Ian R. Judson Martin O. Leach Jerry D. Glickson 《Magnetic resonance in medicine》1995,34(3):338-342
The anticancer agent temozolomide labeled with 13C (8-Carbamoyl-3-13C-methylimidazo-[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one), was noninvasively detected in subcutaneous RIF-1 tumors by a selective cross polarization 13C NMR method, at a field strength of 9.4T. Pharmacokinetics of the drug, at a dose of 150 mg/kg, were determined for intravenous and intraperitoneal modes of administration (three animals per mode). The half-life of the drug in the tumors was approximately 60 min. The uptake and clearance of the drug, however, varied significantly between individual hosts, for both modes of administration. These results demonstrate the feasibility of obtaining pharmacokinetics of anticancer agents for individual tumors without the need for a label that might modify drug activity (e.g., fluorine). The variability of the in vivo measurements, even within the same tumor model, demonstrates the necessity of directly monitoring the tumor to evaluate drug pharmacokinetics. 相似文献